Ko Ta, Yang Chia-Hung, Mao Chun-Tai, Kuo Li-Tang, Hsieh Ming-Jer, Chen Dong-Yi, Wang Chao-Yung, Lin Yu-Sheng, Hsieh I-Chang, Chen Shao-Wei, Hung Ming-Jui, Cherng Wen-Jin, Chen Tien-Hsing
Division of Cardiology, Department of Internal Medicine, Community Medicine Research Center, Chang Gung Memorial Hospital, Keelung; Chang Gung University College of Medicine, Taoyuan.
Division of Cardiology, Department of Internal Medicine, Percutaneous Coronary Intervention Center, Chang Gung Memorial Hospital, Linkou; Chang Gung University College of Medicine, Taoyuan.
Acta Cardiol Sin. 2020 Sep;36(5):416-427. doi: 10.6515/ACS.202009_36(5).20200421A.
Acute coronary syndrome (ACS) is a life-threatening medical condition that accounts for an annual expenditure of more than $300 billion in the United States. Hospital accreditation has been shown to improve patient and hospital outcomes for various conditions.
This study aimed to determine the benefits of hospital accreditation in patients with ACS.
This nationwide population-based cohort study used Taiwan's National Health Insurance Research Database from 1997 to 2011 (n = 249,354). Multivariable logistic regression was used to analyze the risk of in-hospital events among those treated in accredited and non-accredited hospitals, and to compare outcomes in hospitals before and after accreditation. The effect of accreditation on these events was also stratified by accreditation grade.
A total of 823 hospitals were included, of which 2.4% were medical centers, 13.7% were regional hospitals, and 83.8% were district hospitals. The in-hospital mortality [odds ratio (OR), 0.82; 95% confidence interval (CI), 0.79-0.85; p < 0.001] and recurrent acute myocardial infarction (AMI) admission (OR, 0.81; 95% CI, 0.71-0.93; p = 0.003) rates were significantly lower in the after-accreditation group than in the before-accreditation group. There was a substantial and marked decrease in the in-hospital mortality rate after accreditation in 2008.
This cohort study demonstrated that ACS accreditation was associated with better in-hospital mortality and recurrent AMI admission rates in ACS patients.
急性冠状动脉综合征(ACS)是一种危及生命的疾病,在美国每年花费超过3000亿美元。医院评审已被证明可改善各种疾病患者及医院的结局。
本研究旨在确定医院评审对ACS患者的益处。
这项基于全国人群的队列研究使用了1997年至2011年台湾全民健康保险研究数据库(n = 249,354)。采用多变量逻辑回归分析在经评审和未经评审医院接受治疗的患者发生院内事件的风险,并比较医院评审前后的结局。评审对这些事件的影响也按评审等级进行分层。
共纳入823家医院,其中2.4%为医学中心,13.7%为区域医院,83.8%为地区医院。评审后组的院内死亡率[比值比(OR),0.82;95%置信区间(CI),0.79 - 0.85;p < 0.001]和复发性急性心肌梗死(AMI)入院率(OR,0.81;95%CI,0.71 - 0.93;p = 0.003)显著低于评审前组。2008年评审后院内死亡率大幅且显著下降。
这项队列研究表明,ACS评审与ACS患者更好的院内死亡率和复发性AMI入院率相关。